Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates

Cancer

Volumn 116, Issue 3, 2010, Pages 544-573

  Edwards, Brenda K ^a   Ward, Elizabeth ^b   Kohler, Betsy A ^c   Eheman, Christie ^d   Zauber, Ann G ^e   Anderson, Robert N ^f   Jemal, Ahmedin ^b   Schymura, Maria J ^c,g   Lansdorp Vogelaar, Iris ^h   Seeff, Laura C ^d   Van Ballegooijen, Marjolein ^h   Goede, S Luuk ^h   Ries, Lynn A G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

^c North American Association of Central Cancer Registries   (United States)

^d NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f NATIONAL CENTER FOR HEALTH STATISTICS   (United States)

^g New York State Cancer Registry   (United States)

^h ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Cancer Intervention and Surveillance Modeling Network colon models; Colorectal cancer; End results; Epidemiology; Incidence; Microsimulation models; Mortality; National Program of Cancer Registries; North American Association of Central Cancer Registries; Surveillance; United States

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; BREAST CANCER; CANCER CONTROL; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; COLORECTAL CANCER; FEMALE; HEALTH CARE PLANNING; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NOTE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; TREND STUDY; UNITED STATES;

AGED; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; EARLY DIAGNOSIS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; NEOPLASMS; REGISTRIES; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 76249089855     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24760     Document Type: Note

References (163)

1. Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973-1995: a report card for the U.S. Cancer. 1998;82:1197-1207.
2. Wingo PA, Ries LA, Giovino GA, et al. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst. 1999;91:675-690.
3. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst. 2001;93:824-842.
4. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer. 2002;94:2766-2792.
5. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003;95:1276-1299.
6. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004;101:3-27.
7. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97:1407-1427.
8. Howe HL, Wu X, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer. 2006; 107:1711-1742.
9. Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer. 2007; 110:2119-2152.
10. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100:1672-1694.
11. Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer. 2000;88:2398-2424.
12. Fritz A, Percy C, Jack A. International Classification of Diseases for Oncology. Geneva, Switzerland: World Health Organization; 2000.
13. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review 1975-2006. Bethesda, Md: National Cancer Institute; 2009. Available at: http://seer.cancer.gov/csr/ 1975-2006/index.html Accessed August 17, 2009.
14. World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th Rev. Geneva, Switzerland: World Health Organization; 1992.
15. World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death, Adapted for Use in the United States. 6th Rev. Geneva, Switzerland: World Health Organization; 1948.
16. World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death, Adapted for Use in the United States. 7th Rev. Geneva, Switzerland: World Health Organization; 1955.
17. US Department of Health Education and Welfare. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death, Adapted for Use in the United States. 8th Rev. Washington, DC: US Department of Health Education and Welfare, National Center for Health Statistics, Public Health Service; 1968.
18. World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death, Based on the Recommendations of the Ninth Revision Conference, 1975. Geneva, Switzerland: World Health Organization; 1977.
19. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep. 2009;57:1-134.
20. National Cancer Institute, Surveillance Epidemiology and End Results (SEER) Program. Population Estimates Used in NCI's SEER*Stat Software. Available at: http:// seer.cancer.gov/popdata/methods.html Accessed on September 30, 2009.
21. Centers for Disease Control and Prevention. National Center for Health Statistics. National Vital Statistics System. U.S. census populations with bridged race categories. Available at: http://www.cdc.gov/nchs/about/major/dvs/ popbridge/popbridge.htm Accessed March 20, 2008.
22. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Registries Public-Use, November 2008 submission (1973-2006), National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission. Bethesda, Md: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch. Available at: http://www.seer. cancer.gov Accessed on October 6, 2009.
23. Surveillance Research Program, National Cancer Institute. SEER*Stat Software, version 6.5.2. Bethesda, Md: National Cancer Institute; 2009. Available at: http://www.seer.cancer. gov/seerstat Accessed on September 30, 2009.
24. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335-351.
25. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002; 94:1537-1545.
26. NCI. Average Annual Percent Change (AAPC). Available at: http://srab.cancer.gov/joinpoint/aapc.html Accessed September 9, 2009.
27. Clegg LX, Hankey BF, Tiwari R, Feuer EJ, Edwards BK. Estimating average annual percent change in trend analysis. Stat Med. 2009. In press.
28. Feuer EJ, Etzioni R, Cronin KA, Mariotto A. The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing. Stat Methods Med Res. 2004;13:421-442.
29. Vogelaar I, van Ballegooijen M, Schrag D, et al. How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment. Cancer. 2006;107:1624-1633.
30. National Cancer Institute. Colorectal Cancer Mortality Projections. Bethesda, Md: National Cancer Institute; 2007.
31. National Cancer Institute. Cancer Intervention and Surveillance Modeling Network (CISNET). Available at: http://cisnet.cancer.gov/ Accessed August 20, 2009.
32. Morson B. President's Address. The polyp-cancer sequence in the large bowel. Proc R Soc Med. 1974;67(6 pt 1):451-457.
33. Morson BC. Evolution of cancer of the colon and rectum. Cancer. 1974;34:845-849.
34. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer. 1975;36:2251-2270.
35. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Habbema JD. At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. Int J Cancer. 2009;124:1161-1118.
36. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:659-669.
37. National Cancer Institute. Cancer Progress Report - 2003 Update. Bethesda, Md: National Cancer Institute, National Institutes of Health, Department of Health and Human Services; 2004.
38. National Center for Health Statistics. Data File Documentation, National Health Interview Survey, 2003 (machine-readable data file and documentation) [monograph online]. Available at: http://www.cdc.gov/nchs/nhis.htm Accessed May 22, 2006.
39. Winawer SJ. The multidisciplinary management of gastrointestinal cancer. Colorectal cancer screening. Best Pract Res Clin Gastroenterol. 2007;21:1031-1048.
40. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.
41. [No authors listed] Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol. 1999;17:1356-1363.
42. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
43. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18:2938-2947.
44. [No authors listed] Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995;345:939-944.
45. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
46. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
47. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122:321-326.
48. Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol. 1995;13:2936-2943.
49. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-914.
50. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803) [abstract]. J Clin Oncol. 2004;22(suppl 14):A-3500. Abstract 245s.
51. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237.
52. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22:1797-1806.
53. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8 suppl):IV-55-IV-61.
54. Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003; 21:1293-1300.
55. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002; 20:1192-1202.
56. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319.
57. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
58. Tsodikov A, Szabo A, Wegelin J. A population model of prostate cancer incidence. Stat Med. 2006;25:2846-2866.
59. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19:175-181.
60. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009; 101:374-383.
61. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-1792.
62. American Cancer Society. Cancer Facts & Figures 2009. Atlanta, Ga: American Cancer Society; 2009.
63. Sloane D. Cancer epidemiology in the United States: racial, social, and economic factors. Methods Mol Biol. 2009; 471:65-83.
64. Kolb B, Wallace AM, Hill D, Royce M. Disparities in cancer care among racial and ethnic minorities. Oncology (Williston Park). 2006;20:1256-1261; discussion 1261, 1265, 1268-1270.
65. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009;18:1688-1694.
66. Umar A, Greenwald P. Alarming colorectal cancer incidence trends: a case for early detection and prevention. Cancer Epidemiol Biomarkers Prev. 2009;18: 1672-1623.
67. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
68. Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2009; 18:1695-1698.
69. Fairley TL, Cardinez CJ, Martin J, et al. Colorectal cancer in U.S. adults younger than 50 years of age, 1998-2001. Cancer. 2006;107(5 suppl):1153-1161.
70. Meissner HI, Breen N, Klabunde CN, Vernon SW. Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2006;15:389-394.
71. Shapiro JA, Seeff LC, Thompson TD, Nadel MR, Klabunde CN, Vernon SW. Colorectal cancer test use from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2008;17:1623-1630.
72. Brown ML, Potosky AL. The presidential effect: the public health response to media coverage about Ronald Reagan's colon cancer episode. Public Opin Q. 1990;54: 317-329.
73. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365-1371.
74. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343:1603-1607.
75. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134:1570-1595.
76. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology. 2006;130:1872-1885.
77. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149: 627-637.
78. Seeff LC, Richards TB, Shapiro JA, et al. How many endoscopies are performed for colorectal cancer screening? Results from CDC's survey of endoscopic capacity. Gastroenterology. 2004;127:1670-1677.
79. Seeff LC, Nadel MR, Klabunde CN, et al. Patterns and predictors of colorectal cancer test use in the adult U.S. population. Cancer. 2004;100:2093-2103.
80. Klabunde CN, Lanier D, Nadel MR, McLeod C, Yuan G, Vernon SW. Colorectal cancer screening by primary care physicians: recommendations and practices, 2006-2007. Am J Prev Med. 2009;37:8-16.
81. Warren JL, Klabunde CN, Mariotto AB, et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med. 2009;150:849-857, W152.
82. Schatzkin A, Freedman LS, Dawsey SM, Lanza E. Interpreting precursor studies: what polyp trials tell us about large-bowel cancer. J Natl Cancer Inst. 1994;86: 1053-1057.
83. Bernstein CN, McKeown I, Embil JM, et al. Seroprevalence of Helicobacter pylori, incidence of gastric cancer, and peptic ulcer-associated hospitalizations in a Canadian Indian population. Dig Dis Sci. 1999;44:668-674.
84. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol. 2001;96:2992-3003.
85. Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer. 2006;42:216-227.
86. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919-932.
87. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009;11:35-41.
88. Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors [serial online]. PLoS Med. 2009;6:e1000058.
89. Samad AK, Taylor RS, Marshall T, Chapman MA. A meta-analysis of the association of physical activity with reduced risk of colorectal cancer. Colorectal Dis. 2005; 7:204-213.
90. Tomeo CA, Colditz GA, Willett WC, et al. Harvard Report on Cancer Prevention. Volume 3: prevention of colon cancer in the United States. Cancer Causes Control. 1999;10:167-180.
91. Colditz GA, Cannuscio CC, Frazier AL. Physical activity and reduced risk of colon cancer: implications for prevention. Cancer Causes Control. 1997;8:649-667.
92. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr. 2007;86:556-565.
93. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-1638.
94. Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JE. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med. 2004;351:2694-2703.
95. Wang Y, Jacobs EJ, Patel AV, et al. A prospective study of waist circumference and body mass index in relation to colorectal cancer incidence. Cancer Causes Control. 2008; 19:783-792.
96. Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006;98:920-931.
97. Hawley ST, Volk RJ, Krishnamurthy P, Jibaja-Weiss M, Vernon SW, Kneuper S. Preferences for colorectal cancer screening among racially/ethnically diverse primary care patients. Med Care. 2008;46(9 suppl 1):S10-S16.
98. Hu F. Obesity Epidemiology. New York, NY: Oxford University Press; 2008.
99. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2007;86:836S-842S.
100. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:1679-1687.
101. Chao A, Thun MJ, Connell CJ, et al. Meat consumption and risk of colorectal cancer. JAMA. 2005;293:172-182.
102. Cronin KA, Krebs-Smith SM, Feuer EJ, Troiano RP, Ballard-Barbash R. Evaluating the impact of population changes in diet, physical activity, and weight status on population risk for colon cancer (United States). Cancer Causes Control. 2001;12:305-316.
103. Khan LK, Sobush K, Keener D, et al. Recommended community strategies and measurements to prevent obesity in the United States. MMWR Recomm Rep. 2009;58(RR-7):1-26.
104. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Tobacco Smoke and Involuntary Smoking. Lyon, France: International Agency for Research on Cancer; 2004.
105. Department of Health and Human Services. The Health Consequences of Smoking: A Report from the Surgeon General. Washington, DC: Department of Health and Human Services; 2004.
106. Botteri E, Iodice S, Raimondi S, Maisonneuve P, Lowenfels AB. Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology. 2008;134:388-395.
107. Chao A, Thun MJ, Jacobs EJ, Henley SJ, Rodriguez C, Calle EE. Cigarette smoking and colorectal cancer mortality in the Cancer Prevention Study II. J Natl Cancer Inst. 2000;92:1888-1896.
108. Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:725-731.
109. Paskett ED, Reeves KW, Rohan TE, et al. Association between cigarette smoking and colorectal cancer in the Women's Health Initiative. J Natl Cancer Inst. 2007; 99:1729-1735.
110. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10:501-507.
111. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302:649-658.
112. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603-1613.
113. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252-266.
114. Cho E, Smith-Warner SA, Spiegelman D, et al. Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst. 2004;96:1015-1022.
115. Hao Y, Jemal A, Zhang X, Ward EM. Trends in colorectal cancer incidence rates by age, race/ethnicity, and indices of access to medical care, 1995-2004 (United States). Cancer Causes Control. 2009 Jun 19. [Epub ahead of print].
116. Wu X, Cokkinides V, Chen VW, et al. Associations of subsite-specific colorectal cancer incidence rates and stage of disease at diagnosis with county-level poverty, by race and sex. Cancer. 2006;107(5 suppl):1121-1117.
117. NCI. A snapshot of colorectal cancer. NCI-Office of Science Planning and Assessment (OSPA). September 2008. Available at: http://planning.cancer. gov/disease/Colorectal-Snapshot.pdf Accessed August 21, 2009.
118. Mariotto AB, Yabroff KR, Feuer EJ, De Angelis R, Brown M. Projecting the number of patients with colorectal carcinoma by phases of care in the U.S.: 2000-2020. Cancer Causes Control. 2006;17:1215-1226.
119. Yabroff KR, Davis WW, Lamont EB, et al. Patient time costs associated with cancer care. J Natl Cancer Inst. 2007;99:14-23.
120. Howlader N, Ries LA, Stinchcomb DG, Edwards BK. The impact of underreported Veterans Affairs data on national cancer statistics: analysis using population-based SEER registries. J Natl Cancer Inst. 2009;101:533-536.
121. Nelson DE, Powell-Griner E, Town M, Kovar MG. A comparison of national estimates from the National Health Interview Survey and the Behavioral Risk Factor Surveillance System. Am J Public Health. 2003;93:1335-1341.
122. Link MW, Battaglia MP, Frankel MR, Osborn L, Mokdad AH. Address-based versus random-digit-dial surveys: comparison of key health and risk indicators. Am J Epidemiol. 2006;164:1019-1025.
123. Miller BA, Chu KC, Hankey BF, Ries LA. Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S. Cancer Causes Control. 2008;19:227-256.
124. Howe HL, Lake A, Schymura MJ, Edwards BK. Indirect method to estimate specific Hispanic group cancer rates. Cancer Causes Control. 2009;20:1215-1226.
125. Espey DK, Wiggins C, Jim MA, Miller BA, Johnson CJ, Becker TM. Methods for improving cancer surveillance data in American Indian and Alaska Native populations. Cancer. 2008;113(suppl 5):1120-1130.
126. Wingo PA, Tucker TC, Jamison PM, et al. Cancer in Appalachia, 2001-2003. Cancer. 2008;112:181-192.
127. Lengerich EJ, Tucker TC, Powell RK, et al. Cancer incidence in Kentucky, Pennsylvania, and West Virginia: disparities in Appalachia. J Rural Health. 2005; 21:39-47.
128. Becker TM, Espey DK, Lawson HW, Saraiya M, Jim MA, Waxman AG. Regional differences in cervical cancer incidence among American Indians and Alaska Natives, 1999-2004. Cancer. 2008;113(5 suppl):1234-1243.
129. Arias E, Schauman WS, Eschbach K, Sorlie PD, Backlund E. The Validity of Race and Hispanic Origin Reporting on Death Certificates in the United States. Atlanta, Ga: National Center for Health Statistics, Centers for Disease Control; 2008.
130. Institute of Medicine. Ending the Tobacco Problem: A Blueprint for the Nation. Washington, DC: National Academy Press; 2007.
131. Centers for Disease Control and Prevention. Best Practices for Comprehensive Tobacco Control Programs-2007. Atlanta, Ga: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2007.
132. International Agency for Research on Cancer. Weight Control and Physical Activity. Lyon, France: International Agency for Research on Cancer; 2002.
133. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: World Cancer Research Fund/American Institute for Cancer Research; 2007.
134. Kushi LH, Byers T, Doyle C, et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2006; 56:254-281; quiz 313-254.
135. Harriss DJ, Atkinson G, Batterham A, et al. Lifestyle factors and colorectal cancer risk: a systematic review and meta-analysis of associations with leisure-time physical activity. Colorectal Dis. 2009;11:689-701.
136. Centers for Disease Control. CDC Weight of the Nation Conference. Available at: http://www.cdc.gov/media/transcripts/ 2009/t090727.htm Accessed August 19, 2009.
137. Finkelstein EA, Brown DS, Wrage LA, Allaire BT, Hoerger TJ. Individual and aggregate years-of-life-lost associated with overweight and obesity. Obesity (Silver Spring). 2009 Aug 13. [Epub ahead of print].
138. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer- and service-specific estimates [serial online]. Health Aff (Millwood). 2009;28;w822-w831.
139. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670-1674.
140. Cronin KA, Ravdin PM, Edwards BK. Sustained lower rates of breast cancer in the United States. Breast Cancer Res Treat. 2009;117:223-224.
141. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat. 2008;107:427-430.
142. Mason JB, Dickstein A, Jacques PF, et al. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev. 2007;16:1325-1329.
143. National Cancer Institute. Colorectal Cancer: Six Years of Research Progress. Bethesda, Md: National Cancer Institute; 2008.
144. Houlston RS, Webb E, Broderick P, et al. Meta-analysis of genome-wide association data identifies 4 new susceptibility loci for colorectal cancer. Nat Genet. 2008;40:1426-1435.
145. Taplin SH, Haggstrom D, Jacobs T, et al. Implementing colorectal cancer screening in community health centers: addressing cancer health disparities through a regional cancer collaborative. Med Care. 2008;46(9 suppl 1):S74-S83.
146. Zapka J. Innovative provider- and health system-directed approaches to improving colorectal cancer screening delivery. Med Care. 2008;46(9 suppl 1):S62-S67.
147. NCCRT. National Colorectal Cancer Roundtable. Available at: http://www.nccrt.org/ Accessed September 16, 2009.
148. National Institutes of Health. NIH State-of-the-Science Conference: Enhancing Use and Quality of Colorectal Cancer Screening. Available at: http://consensus.nih.gov/ Accessed August 26, 2009.
149. Hosein PJ, Rocha-Lima CM. Role of combined-modality therapy in the management of locally advanced rectal cancer. Clin Colorectal Cancer. 2008;7:369-375.
150. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677-3683.
151. Grothey A, Marshall JL. Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy. Oncology (Williston Park). 2007;21:553-564,566; discussion 566-568,577-578.
152. Hamilton SR. Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod Pathol. 2008; 21(suppl 2):S23-S30.
153. Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H, Ajani JA. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. Cancer. 2009;115:3609-3617.
154. Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. Annu Rev Med. 2009;60:207-219.
155. Marshall JL, Gehan EA. The development of novel agents for the treatment of colorectal cancer: a critical review of current practice and some suggestions for the future. Clin Adv Hematol Oncol. 2007;5:167-172.
156. Lang K, Korn JR, Lee DW, Lines LM, Earle CC, Menzin J. Factors associated with improved survival among older colorectal cancer patients in the U.S.: a population-based analysis [serial online]. BMC Cancer. 2009;9:227.
157. Berry J, Bumpers K, Ogunlade V, et al. Examining racial disparities in colorectal cancer care. J Psychosoc Oncol. 2009; 27:59-83.
158. Rolnick S, Hensley Alford S, Kucera GP, et al. Racial and age differences in colon examination surveillance following a diagnosis of colorectal cancer. J Natl Cancer Inst Monogr. 2005;96-101.
159. Alexander DD, Waterbor J, Hughes T, Funkhouser E, Grizzle W, Manne U. African-American and Caucasian disparities in colorectal cancer mortality and survival by data source: an epidemiologic review. Cancer Biomark. 2007; 3:301-313.
160. Chanock SJ, Hunter DJ. Genomics: when the smoke clears. Nature. 2008;452:537-538.
161. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature. 2008;452:553-563.
162. Carr KM, Rosenblatt K, Petricoin EF, Liotta LA. Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. Hum Genomics. 2004;1:134-140.
163. Feero WG, Guttmacher AE, Collins FS. The genome gets personal - almost. JAMA. 2008;299:1351-1312.